BTIG analyst Marie Thibault maintained a Hold rating on Viewray (VRAY) on January 21. The company’s shares closed last Friday at $4.44.
According to TipRanks.com, Thibault is a top 100 analyst with an average return of 101.6% and a 67.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Irhythm Technologies.
Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $5.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.36 and a one-year low of $1.11. Currently, Viewray has an average volume of 1.9M.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRAY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
